These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29729495)

  • 1. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
    Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D
    Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting
    Baik CS; Myall NJ; Wakelee HA
    Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
    Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
    J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Li J; Wang Q; Ge J; Tian Y; Yao W
    Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic predictors of MEK dependence in non-small cell lung cancer.
    Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
    Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
    Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA
    Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    Jiang L; Yang P; Liu Y; Li J
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
    Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
    Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
    Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;
    Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
    Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib and trametinib for the treatment of non-small cell lung cancer.
    Kelly RJ
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1063-1068. PubMed ID: 30198802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
    Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
    Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF-mutations in non-small cell lung cancer.
    Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å
    Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.